Genixus, a company focused on manufacturing and designing drug delivery systems, announced that it would build a 30,000-square-foot in North Carolina, US. The company stated that the site would be outfitted with automated manufacturing equipment to support its KinetiX syringe platform.
KinetiX is a ready-to-administer syringe platform, which is made from a plastic polymer rather than glass. The syringes feature a color-coded label and a color-coded plunger rod, making them suitable for quick identification, and to support verification and tracking, Genixus stated.
In line with the expansion of its facilities, the company plans to triple its staff numbers by the end of 2024. The new facility will be built in Concord, New Carolina, while Genixus also holds capacity to manufacture the KinetiX syringe at its headquarters in Kannapolis, also in North Carolina.
At present, the company has only one product, in the form of KinetiX RTA Propofol, which is available in 10ml and 20ml sizes. The product was released in August 2022, following the 503B registration and licensing of the company’s existing manufacturing space in North Carolina.
“The finalized fit out, featuring new state-of-the-art syringe production and isolators, significantly expands our production and will play a pivotal role in addressing the demand for Propofol and our launch of additional KinetiX products in the second half of 2023,” said Kendall Foster, CEO of Genixus.
The buildout will include clean rooms for formulation, filling, inspection, and packaging. In addition, the company stated that there will be quality control laboratories and dedicated utilities.
Beyond providing capacity for its KinetiX products, the company stated that the new facility will hold an option for expanding to adapt to demand.
In terms of the KinetiX Propofol features, Genixus stated that the syringes have long-term shelf stability, can be dispensed through an auto-dispensing cabinet, as well as being radio frequency identification (RFID)-enabled for kit and tray management.
The latter element was provided when Genixus partnered with Kit Check in August 2022. Kit Check provides RFID tags for medications, which helps manufacturers to ensure item-level visibility of drug products through their lifecycle.
RFID tags record data for each dose, such as lot number, national drug code, and refrigeration date. This can aid in the process of managing drug shortages, drug recalls, restocking medications, and monitoring inventory.